111’s (YI) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 111 (NASDAQ:YI) in a report released on Wednesday,Weiss Ratings reports.

111 Stock Performance

Shares of YI opened at $8.08 on Wednesday. The firm has a market cap of $69.84 million, a price-to-earnings ratio of -2.02 and a beta of 0.47. 111 has a fifty-two week low of $4.15 and a fifty-two week high of $12.90. The firm has a 50 day moving average price of $7.86 and a 200-day moving average price of $7.59.

111 (NASDAQ:YI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $527.14 million for the quarter.

Institutional Investors Weigh In On 111

Large investors have recently bought and sold shares of the business. FIL Ltd purchased a new position in 111 during the fourth quarter worth $450,000. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in 111 in the fourth quarter worth about $245,000. JPMorgan Chase & Co. lifted its stake in 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after acquiring an additional 305,339 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in 111 in the first quarter worth about $92,000. Finally, Deuterium Capital Management LLC purchased a new stake in shares of 111 during the first quarter valued at about $81,000. Institutional investors own 21.32% of the company’s stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.